Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Start Learning

Touch Loading image
touchMEETING HIGHLIGHTS
Start Learning
Precision oncology – predicting future risk in early breast cancer (eBC)
Sponsored content
JOURNALS
Start Learning
Dostarlimab for the Treatment of Endometrial Cancer: A Review
JOURNALS
Start Learning
Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer
JOURNALS
Start Learning
Advances in GVHD: Highlights from EBMT 2024
touchMDT
Start Learning
Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
CE/CME ACCREDITED
touchEXPERT OPINIONS
Start Learning
What’s on the horizon to tackle unmet needs in recurrent/metastatic SCCHN?
CE/CME ACCREDITED
touchEXPERT OPINIONS
Start Learning
Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape
CE/CME ACCREDITED
JOURNALS
Start Learning
Advancing precision medicine: ESMO updates tumour NGS guidelines 
Esophagus or oesophagus 3D rendering illustration close-up with male body contours. Human anatomy, esophagitis, acid reflux, digestive system, medical, biology, science, medicine, healthcare concepts.
JOURNALS
Start Learning
Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives
CONFERENCE HUB
Start Learning
PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld

to view Favourites, Keep Notes and Track CME Credits

Favourites
PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld
View
Precision targeting of MET in NSCLC: A multidisciplinary approach
View
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
View
Advancing precision medicine: ESMO updates tumour NGS guidelines 
View
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
View
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
View
New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy
View
Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer
View
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
View
Project Cure CRC pushes for cutting-edge innovations in colorectal cancer care
View
In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup